Huang Yonglian, Chen Yanhong, Cai Hairong, Chen Dongjie, He Xiaoming, Li Zhixiong, Cai Xiaojing, Peng Xiaohong, Huang Yaxiu, Li Shaoping, Cao Qifeng, Wang Ping, Chen Bojun
Department of Critical Care Medicine, Beijing University of Chinese Medicine Shenzhen Hospital.
The Second Clinical College, Guangzhou University of Chinese Medicine.
Medicine (Baltimore). 2019 Feb;98(6):e14292. doi: 10.1097/MD.0000000000014292.
Essential hypertension is one of the most common chronic diseases worldwide, as well as a leading risk factor for cardiocerebrovascular diseases. Zhengan Xifeng Decoction (ZGXFD) has been widely used to treat essential hypertension, but there is no systematic review by assessing efficacy and safety of ZGXFD on essential hypertension. Therefore, we aim to perform systematic review and meta-analysis to evaluate the efficacy and safety of ZGXFD in the treatment of essential hypertension.
This systematic review and meta-analysis will be performed by means of electronic databases, including EMBASE, Cochrane Center Registration Controlled trials (Cochrane Library), Web of Science (WOS), World Health Organization International Clinical Trials Registry Platform, PubMed, China Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), and Wan-fang database. The electronic databases will be searched from their inception to October 2018. This systemic review will include only published English and Chinese articles randomized controlled trials (RTCs) of ZGXFD on essential hypertension. The primary outcome is Efficacy and blood pressure (BP), blood lipid and adverse reactions will be accepted as secondary outcomes. All statistical analyses will be conducted using RevMan V.5.3.5 software.
This systematic review and meta-analysis will provide high-quality evidence from several aspects, including for efficacy, blood pressure, blood lipid and adverse effects to evaluate the efficacy and safety of ZGXFD on EHTN.
This systematic review will determine whether or not ZGXFD is an effective intervention for essential hypertension.
原发性高血压是全球最常见的慢性病之一，也是心脑血管疾病的主要危险因素。镇肝熄风汤已被广泛用于治疗原发性高血压，但尚未有通过评估其治疗原发性高血压的疗效和安全性进行的系统评价。因此，我们旨在进行系统评价和荟萃分析，以评估镇肝熄风汤治疗原发性高血压的疗效和安全性。
本系统评价和荟萃分析将通过电子数据库进行，包括EMBASE、Cochrane中心对照试验注册库（Cochrane图书馆）、科学引文索引（Web of Science，WOS）、世界卫生组织国际临床试验注册平台、PubMed、中国生物医学文献数据库（CBM）、中国知网（CNKI）、维普中文科技期刊数据库（VIP）和万方数据库。电子数据库将从建库至2018年10月进行检索。本系统评价仅纳入已发表的关于镇肝熄风汤治疗原发性高血压的英文和中文随机对照试验（RCT）。主要结局为疗效和血压，血脂及不良反应将作为次要结局。所有统计分析将使用RevMan V.5.3.5软件进行。
本系统评价和荟萃分析将从多个方面提供高质量证据，包括疗效、血压、血脂及不良反应，以评估镇肝熄风汤治疗原发性高血压的疗效和安全性。
本系统评价将确定镇肝熄风汤是否为原发性高血压的有效干预措施。
